Anaphylaxis Treatment Global Market Report 2024

The anaphylaxis treatment market size has grown strongly in recent years. It will grow from $5.73 billion in 2023 to $6.15 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth observed in the historical period can be attributed to several factors, including a rise in the incidence of allergic reactions, heightened awareness and recognition of anaphylaxis, increased availability of epinephrine auto-injectors, and efforts focused on public awareness and education. Additionally, there has been a notable emphasis on training healthcare professionals to better manage and respond to anaphylactic reactions. These combined factors have contributed to the historical growth in addressing and treating allergic emergencies.

The anaphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $7.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth in the forecast period can be attributed to ongoing innovation in biologic therapies, the development of customized treatment approaches, global initiatives focused on food safety, increased patient empowerment and advocacy, and advancements in emergency medical services. Additionally, notable trends in the forecast period include continued innovation in auto-injectors, the integration of telemedicine for anaphylaxis management, advancements in allergen immunotherapy, the utilization of biometric wearables for allergen detection, and collaborative efforts in allergy research. These trends collectively contribute to the expected expansion of strategies and technologies for addressing anaphylaxis.

The escalating prevalence of food allergies is anticipated to drive the expansion of the anaphylaxis treatment market in the foreseeable future. Food allergies, characterized by an immune response to specific proteins in food, necessitate effective anaphylaxis treatments to counter potentially life-threatening allergic reactions. For instance, according to the Centers for Disease Control and Prevention's January 2023 report, 31.8% of adults in 2021 reported conditions such as eczema, seasonal allergies, or food allergies. Among them, 25.7% reported seasonal allergies, 6.2% had food allergies, and 7.3% were afflicted by eczema. This surge in food allergies is significantly contributing to the growing demand for anaphylaxis treatments.

The upsurge in healthcare spending is projected to fuel the growth of the anaphylaxis treatment market in the coming years. Healthcare expenditure, representing the total financial outlay on healthcare services and products within a specific region or healthcare system, plays a pivotal role in facilitating access to anaphylaxis treatments. Increased spending can facilitate enhanced accessibility to life-saving medications, greater investments in research and development, diversification of treatment options, fortification of emergency response systems, and the implementation of preventive measures. For instance, as per the UK's Office for National Statistics in May 2023, healthcare spending in the UK surged by 9.4% nominally and 9.7% practically. The total healthcare expenditure in 2021 amounted to $367.25 billion (£280.7 billion), with pharmaceutical costs at $51.84 billion (£39.6 billion), and significant allocations of $45.93 billion (£35.1 billion) to preventive care. This substantial increase in healthcare spending is contributing to the expansion of the anaphylaxis treatment market.

Advancements in product development mark a significant trend in the anaphylaxis treatment market. Major industry players are intensifying their product innovations to maintain a competitive edge. For example, in April 2022, Aquestive Therapeutics Inc., a US-based pharmaceutical firm, secured Fast Track designation from the Food and Drug Administration for AQST-109, an orally administered epinephrine product candidate designed for treating severe allergic responses, including anaphylaxis. This pioneering solution is a notable milestone, showing comparable clinical outcomes to autoinjectors such as EpiPen and Auvi-Q in managing allergic emergencies.

Companies at the forefront of the anaphylaxis treatment market are prioritizing innovative solutions such as the sulfite-free epinephrine injection to drive market growth. This injection, a crucial life-saving medication for severe allergic reactions, has witnessed advancements in its formulations. For instance, in March 2023, American Regent Inc., a leading US-based pharmaceutical company, launched a sulfite-free epinephrine injection USP. This product, suitable for subcutaneous, intramuscular, and intravenous administration, boasts a formulation devoid of sulfites or preservatives. Notably, it's recommended for adult patients experiencing hypotension due to septic shock to elevate mean arterial blood pressure.

In October 2023, the US-based biopharmaceutical company Amgen Inc. completed the acquisition of Horizon Therapeutics Plc for a substantial sum of $27.8 billion. This strategic move positions Amgen to expand its product portfolio, enabling the company to provide treatments for severe inflammatory, autoimmune, and rare disorders. The acquisition underscores Amgen's commitment to leveraging biotechnology to address the healthcare needs of patients facing life-threatening conditions. Horizon Therapeutics PLC, based in Ireland, is a biopharmaceutical company with a focus on developing innovative therapeutic solutions.

Major companies operating in the anaphylaxis treatment market report are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Abbott Laboratories, GlaxoSmithKline PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Bausch Health Companies, Sun Pharmaceutical Industries Ltd., Perrigo Co, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., ALK-Abelló A/S, Amphastar Pharmaceuticals Inc., Par Pharmaceutical Inc., Genentech Inc., MannKind Corporation, Meridian Medical Technologies LLC, Aquestive Therapeutics Inc., Sandoz Inc., Bioprojet SCR, Adamis Pharmaceutical Corporation, Impax Laboratories LLC.

North America was the largest region in the anaphylaxis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaphylaxis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anaphylaxis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key treatments for anaphylaxis include epinephrine, antihistamines, steroids, beta-antagonists, and other supportive measures. Epinephrine, a synthetic or extracted form of adrenaline, is the primary and essential therapy for anaphylaxis. It must be administered promptly upon identifying the condition to prevent the onset of severe symptoms. These treatments are available in various forms such as tablets and capsules and are distributed through hospital pharmacies, retail pharmacies, and online platforms, addressing allergies such as food allergies, pollen allergies, dust mite allergies, and others.

The anaphylaxis treatment market research report is one of a series of new reports that provides anaphylaxis treatment market statistics, including anaphylaxis treatment industry global market size, regional shares, competitors with an anaphylaxis treatment market share, detailed anaphylaxis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anaphylaxis treatment industry. This anaphylaxis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anaphylaxis treatment market consists of sales of bronchodilators, corticosteroids, and vasopressors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.